Real World Evidence
Retrospective studies using administrative claims data to understand aspects of health care cost and utilization for patients with iron deficiency anemia.
This section includes links to Pharmacosmos sponsored- publications and selected Pharmacosmos posters. Information contained in these publications may include information that is inconsistent with the FDA approved use of product(s). Pharmacosmos does not recommend the use of its products in a manner that is inconsistent with FDA-approved labeling. Additionally, the content contained in this section is subject to congress copyright permissions.
October 15-17, 2025 I NCODA Fall Summit (Poster)
Ferric Derisomaltose Achieves Highest Likelihood of ≥1,000 mg Dose Administered and Lowest Outpatient Transfusion Rates Among IV Iron Therapies in Women with Iron Deficiency Anemia and Abnormal Uterine Bleeding: A Real-World Analysis
Von Drygalski A, Boland P, Maksour M, et al.
May 13-16, 2025 I ISPOR (Poster)
Optimizing adherence to intravenous iron, a geographic analysis of variability within the United States: Single-dose ferric derisomaltose shows highest adherence across healthcare plans & geographies
Beavers CJ, Armstrong L, Polson M, et al.
April 23-25, 2025 I NCODA Spring Forum (Poster)
Single-dose ferric derisomaltose had the highest adherence among intravenous iron therapy in a national community oncology network real-world analysis
Chang M, Mulherin B, Patel T, et al.
March 31-April 3, 2025 I AMCP (Poster)
Impact of geographic location on intravenous iron treatment adherence in urban, rural, and super rural regions: Single-dose IV iron ferric derisomaltose demonstrated the highest adherence rate that was not affected by the region
Shatzel J, Polson M, Novak J
May 5-8, 2024 I ISPOR (Poster)
Enhancing oncology model: Discordance among patients using intravenous iron in the US
Ratnam S, Polson M
May 5-8, 2024 I ISPOR (Poster)
Impact of COVID-19 pandemic on IVI iron (IVI) cost and utilization in commercially-insured patients with iron deficiency anemia
Polson M, Winegar B, Kidd S
April 15-18, 2024 I AMCP (Poster)
Intravenous iron treatment considerations in patients with non-dialysis dependent chronic kidney disease
Upadhyay A, Polson M
April 15-18, 2024 I AMCP (Poster)
Management of iron deficiency anemia in oncology: Intravenous iron discordance in cancer patients
Page RD, Narang M, Polsen M
July 2023 I J Manag Care Spec Pharm
Financial burden associated with discordance to intravenous iron therapies in US patients with iron deficiency anemia
Polson MK, Bahrain H, Ogden JF et al.
March 29-April 1, 2022 I AMCP (Poster)
Financial burden associated with discordance to intravenous iron therapies in US patients with iron deficiency anemia
Polson M, Utkina K, Bucco R, et al.